Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vebicorvir + AB-729 in Chronic Hepatitis B
NCT04820686Phase 2Terminated
- Sponsor
- Assembly Biosciences, Inc.
- Start
- May 2021
- Primary completion
- Mar 2023
- Modality
- Gene Editing, Gene Silencing, Conjugated siRNA
- Countries
- 4
01
Overview
A Phase 2 trial of vebicorvir, imdusiran in Chronic Hepatitis B (CHB), sponsored by Assembly Biosciences, Inc.. Started May 2021; status: terminated.
02
Drugs
vebicorvirimdusiran
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04820686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04820686.